NYSE:MED - Medifast Stock Price, News, & Analysis

Medifast trades on the New York Stock Exchange (NYSE) under the ticker symbol "MED."

Medifast declared a quarterly dividend on Wednesday, December 12th. Shareholders of record on Friday, December 21st will be paid a dividend of $0.75 per share on Thursday, February 7th. This represents a $3.00 dividend on an annualized basis and a yield of 2.30%. The ex-dividend date of this dividend is Thursday, December 20th. This is a positive change from Medifast's previous quarterly dividend of $0.48. View Medifast's Dividend History.

Medifast Inc (NYSE:MED) issued its earnings results on Thursday, August, 2nd. The specialty retailer reported $1.16 EPS for the quarter, topping the consensus estimate of $0.98 by $0.18. The specialty retailer had revenue of $117.30 million for the quarter, compared to the consensus estimate of $101.75 million. Medifast had a return on equity of 43.45% and a net margin of 10.95%. The company's revenue for the quarter was up 55.0% compared to the same quarter last year. During the same period last year, the business posted $0.63 earnings per share. View Medifast's Earnings History.

Medifast is scheduled to release their next quarterly earnings announcement on Tuesday, February 26th 2019. View Earnings Estimates for Medifast.

Medifast issued an update on its FY18 earnings guidance on Monday, January, 14th. The company provided earnings per share (EPS) guidance of $4.45-4.50 for the period, compared to the Thomson Reuters consensus EPS estimate of $4.50. The company issued revenue guidance of $492.5-497.5 million, compared to the consensus revenue estimate of $497.04 million.

2 equities research analysts have issued 1-year price objectives for Medifast's shares. Their forecasts range from $249.00 to $249.00. On average, they expect Medifast's stock price to reach $249.00 in the next year. This suggests a possible upside of 90.6% from the stock's current price. View Analyst Price Targets for Medifast.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Medifast in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Medifast.

News headlines about MED stock have been trending positive recently, InfoTrie reports. The research group identifies positive and negative press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Medifast earned a media sentiment score of 2.7 on InfoTrie's scale. They also gave media headlines about the specialty retailer a news buzz of 6.0 out of 10, meaning that recent press coverage is somewhat likely to have an effect on the stock's share price in the next few days.

Some companies that are related to Medifast include MCCORMICK & CO /SH (MKC), WANT WANT CHINA/ADR (WWNTY), Greencore Group (GNCGY), Farmer Bros (FARM), China Marine Food Group (CMFO) and Jammin Java (JAMN).

Medifast's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (14.23%), Dimensional Fund Advisors LP (5.50%), Acadian Asset Management LLC (3.62%), MERIAN GLOBAL INVESTORS UK Ltd (2.54%), Principal Financial Group Inc. (1.80%) and Bank of New York Mellon Corp (1.63%). Company insiders that own Medifast stock include Charles P Connolly, Constance J Hallquist, Daniel R Chard, Glenn W Welling, Jeremy John Martin, Michael A Hoer, Michael C Macdonald, Ralph Rushton and Simon TP Ridgway. View Institutional Ownership Trends for Medifast.

MED stock was sold by a variety of institutional investors in the last quarter, including WINTON GROUP Ltd, O Shaughnessy Asset Management LLC, Prudential Financial Inc., KBC Group NV, Dimensional Fund Advisors LP, SG Americas Securities LLC, Nisa Investment Advisors LLC and Hsbc Holdings PLC. Company insiders that have sold Medifast company stock in the last year include Charles P Connolly, Constance J Hallquist and Michael C Macdonald. View Insider Buying and Selling for Medifast.

MED stock was acquired by a variety of institutional investors in the last quarter, including MERIAN GLOBAL INVESTORS UK Ltd, Millennium Management LLC, Intrinsic Edge Capital Management LLC, Assenagon Asset Management S.A., Bank of America Corp DE, Principal Financial Group Inc., First Trust Advisors LP and Voloridge Investment Management LLC. Company insiders that have bought Medifast stock in the last two years include Daniel R Chard, Glenn W Welling, Michael A Hoer and Simon TP Ridgway. View Insider Buying and Selling for Medifast.

Shares of MED can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of MED stock can currently be purchased for approximately $130.64.

Medifast has a market capitalization of $1.56 billion and generates $301.56 million in revenue each year. The specialty retailer earns $27.72 million in net income (profit) each year or $2.29 on an earnings per share basis. Medifast employs 399 workers across the globe.

The official website for Medifast is http://www.medifast1.com.

Medifast's mailing address is 100 International Drive, Baltimore MD, 21202. The specialty retailer can be reached via phone at 410-581-8042 or via email at [email protected]